PF 6425090

Drug Profile

PF 6425090

Alternative Names: Clostridium difficile vaccine - Pfizer; PF-06425090; PF-6425090

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Pfizer
  • Class Bacterial vaccines; Subunit vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Clostridium infections
  • New Molecular Entity No

Highest Development Phases

  • Phase II Clostridium infections

Most Recent Events

  • 04 Jul 2016 Pfizer plans a phase III trial for Clostridium infections in United Kingdom (IM) (UKCRN31054)
  • 01 Feb 2016 Phase-I clinical trials in Clostridium infections (In the elderly, In volunteers) in Japan (IM) (NCT02725437)
  • 01 Jul 2015 Pfizer initiates enrolment in a phase II trial for Clostridium infections (In volunteers, In elderly) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top